GRI Bio amends warrants; raises $0.8M by reducing exercise price to $1.00

GRI Bio, Inc.

Entered repricing agreements for 762,236 Series B warrants; holders exercise at $1.00/share (down from $14.30) for gross proceeds of $762,236.
Issued new Series D-1 (5-year term) and Series D-2 (18-month term) warrants, also exercisable at $1.00/share.
Net proceeds to be used for working capital and general corporate purposes; offering closed October 22, 2024.
H.C. Wainwright acted as placement agent, receiving 7% cash fee plus 1% management fee and warrants to purchase 53,357 shares at $1.25.
New warrants and shares issued in unregistered private placement under Section 4(a)(2) and Regulation D; resale registration to be filed within 30 days.

item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.